SCHEMBL2442267

SCHEMBL2442267

COC(=O)c1ccccc1NC=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.65
POLB P06746 1/20 0.65
ATM Q13315 1/20 0.65
MAPT P10636 3/20 0.59
ALOX15 P16050 1/20 0.59
KMT2A Q03164 1/20 0.59
GLA P06280 1/20 0.56
SMN1; SMN2 Q16637 3/20 0.55
HPGD P15428 3/20 0.55
HTT P42858 1/20 0.55
ALDH1A1 P00352 7/20 0.55
RAB9A P51151 1/20 0.55
HSD17B10 Q99714 7/20 0.54
TSHR P16473 5/20 0.53
LMNA P02545 2/20 0.53
GAA P10253 2/20 0.53
MAPK1 P28482 1/20 0.53
CFTR P13569 1/20 0.52
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29483352 1.00 KDM4E (0.65) KDM4EPOLBATMMAPTALOX15
SCHEMBL28528095 0.98 KDM4E (0.62) KDM4EPOLBATMMAPTALOX15
Formic Acid SCHEMBL16769071 0.92 KDM4E (0.56) KDM4EPOLBATMMAPTALOX15
SCHEMBL4753944 0.84 CXCR2 (0.52) KDM4EPOLBATMMAPTALOX15
SCHEMBL18230844 0.84 KDM4E (0.62) KDM4EPOLBATMMAPTALOX15
SCHEMBL30978353 0.84 KDM4E (0.62) KDM4EPOLBATMMAPTALOX15
Methyl Nicotinate SCHEMBL28249346 0.83 ALDH1A1 (0.64) KDM4EPOLBATMMAPTKMT2A
SCHEMBL8115291 0.83 ADRA1A (0.48) KDM4EPOLBATMMAPTALOX15
SCHEMBL8105194 0.83 ADRA1D (0.48) KDM4EPOLBATMMAPTALOX15
SCHEMBL5525906 0.83 CASP3 (0.64) KDM4EMAPTKMT2AHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1299354-B1 FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE SANOFI AVENTIS DEUTSCHLAND (DE) 2009-07-22 EP claimed
WO-2008017840-A1 CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIOUS DISEASES MERLION PHARMACEUTICALS SA (CH) 2008-02-14 WO claimed
EP-1189891-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION Bioscience AG (DE) 2002-03-27 EP claimed
US-6362342-B1 BIOSYNTHESIS; DRUG LIBRARIES LION BIOSCIENCE AG (DE) 2002-03-26 US claimed
WO-2001000594-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2001-01-04 WO claimed
EP-0322448-B1 A METHOD FOR THE PREPARATION OF \"NATURAL\" METHYL ANTHRANILATE BASF K & F CORP (US) 1993-11-10 EP claimed
US-5200330-A Microbial N-dimethylation of methyl N-methyl anthranilate BASF K&F CORPORATION (US) 1993-04-06 US claimed
WO-2024182515-A1 AGENTS FOR REPELLING, KNOCKING DOWN, AND/OR KILLING BLOOD-SUCKING ARTHROPODS AND USES THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 2024-09-06 WO disclosed
US-20240292836-A1 AGENTS FOR REPELLING, KNOCKING DOWN, AND/OR KILLING BLOOD-SUCKING ARTHROPODS AND USES THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE 2024-09-05 US disclosed
EP-2775839-B1 METHODS FOR ASSESSING REPELLANT QUALITY OF ORGANIC MATERIALS AND METHODS AND COMPOSITIONS FOR REPELLING ARTHROPODS UNIV CALIFORNIA (US) 2023-12-06 EP disclosed
EP-3416729-B1 PRO-FRAGRANCE COMPOSITION AQDOT LTD (GB) 2023-09-20 EP disclosed
CN-113462471-B Plastic particle flavoring essence and preparation method thereof 上海意安实业有限公司 2023-05-09 CN disclosed
CN-110891615-B System and method for selecting and releasing fragrance 阿甘香气及精细化学有限公司 2022-08-05 CN disclosed
US-6743790-B2 A UREA OR THIOUREA DERIVATIVES CONTAINING AMIDE GROUP USEFUL AS ANTICOAGULANTS AND ANTIINFLAMMATORY AGENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-06-01 US disclosed
EP-1299354-A2 FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE Aventis Pharma Deutschland GmbH (DE) 2003-04-09 EP disclosed
US-6362342-B1 BIOSYNTHESIS; DRUG LIBRARIES LION BIOSCIENCE AG (DE) 2002-03-26 US disclosed
WO-2001094301-A2 FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-12-13 WO disclosed
US-6114546-A Aminomethylene derivatives and ultraviolet absorbent comprising thereof CHEMIPRO KASEI KAISHA, LIMITED (JP) 2000-09-05 US disclosed
EP-0950655-A1 AMINOMETHYLENE DERIVATIVES AND ULTRAVIOLET ABSORBER COMPRISING THE SAME CHEMIPRO KASEI KAISHA, LIMITED (JP) 1999-10-20 EP disclosed
US-5939398-A ANTIATHEROSCLEROSIS AGENTS PFIZER INC. (US) 1999-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240292836-A1 AGENTS FOR REPELLING, KNOCKING DOWN, AND/OR KILLING BLOOD-SUCKING ARTHROPODS AND USES THEREOF L3MBTL4, L3MBTL3, L3MBTL1 KDM4E 276/4885POLB 1747/4885ATM 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.